Heparin vials from a specific supplier (Fresenius Kabi) appear to be ineffective, requiring abnormally high doses to achieve therapeutic ACT levels during PCI procedures, causing frustration among cli

Heparin vials from a specific supplier (Fresenius Kabi) appear to be ineffective, requiring abnormally high doses to achieve therapeutic ACT levels during PCI procedures, causing frustration among clinical staff and reluctance from management to switch suppliers.